2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC
  5. Drug-Linker Conjugates for ADC Isoform

Drug-Linker Conjugates for ADC

 

Drug-Linker Conjugates for ADC Related Products (239):

Cat. No. Product Name Effect Purity
  • HY-170587
    Glucocorticoid receptor drug-linke 1
    Glucocorticoid receptor drug-linke 1 is a drug-linker conjugate, that can be used for synthesis of BDCA2-targeting ADC.
  • HY-153962
    SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3
    SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a Drug-Linker Conjugate for ADC. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
  • HY-176559
    LacNAc-VC-PAB-MMAE
    LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab (HY-P9907) by WT Endo-S2.
  • HY-171931A
    Aminocaproyl-Val-Cit-PABC-Exatecan TFA
    		99.18%
    Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis.
  • HY-148339
    Fmoc-VAP-MMAE
    Fmoc-VAP-MMAE is a agent-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE (HY-15162), with a protective Fmoc group.
  • HY-157284
    Cys-mc-MMAE
    		99.85%
    Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs.
  • HY-176765
    DBCO-PEG4-VA-PABC-MMAE
    DBCO-PEG4-VA-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG4-VA-PABC-MMAE consists of a tubulin inhibitor (MMAE) (HY-15162) and a cleavable linker (DBCO-PEG4-VA-PABC). DBCO-PEG4-VA-PABC-MMAE can be used for synthesis of ADC ABBV-400 (HY-171945).
  • HY-159563
    Mal-va-mac-SN38
    Mal-va-mac-SN38 is a drug-linker conjugate for ADC. Mal-va-mac-SN38 contains a ADC cytotoxin SN-38 (HY-13704) and a linker (HY-126364). Mal-va-mac-SN38 can rapidly and covalently bind with endogenous albumin in vivo, resulting in the formation of HSA-va-mac-SN38. Mal-va-mac-SN38 demonstrates exceptional stability in human plasma, and has anti-tumor and anti-metastasis effect.
  • HY-13631O
    (1R)-Deruxtecan
    		99.32%
    (1R)-Deruxtecan is a drug-linker conjugates for ADC.
  • HY-153428
    GGGDTDTC-Mc-vc-PAB-MMAE
    		99.75%
    GGGDTDTC-Mc-vc-PAB-MMAE is a Drug-Linker Conjugate for ADC, containing a tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162).
  • HY-160899A
    Thailanstatin A cyclohexane diamine formic
    Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC50 is 0.33 μM), BT474 (IC50 is 0.34 μM), MDA-MB-361-DYT2 (IC50 is 0.88 μM) and MDA-MB-468 (IC50 is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule.
  • HY-163549
    APN-PEG5-VC-PAB-MMAE
    APN-PEG5-VC-PAB-MMAE is a drug-linker conjugate part of INA03 (a transferrin-competitive antibody-drug conjugate against CD71).
  • HY-148346A
    STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA
    		98.30%
    STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer.
  • HY-145989S
    Aminobenzenesulfonic auristatin E-d8
    		98.02%
    Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.
  • HY-178836
    Z56-L23
    Z56-L23 is Drug-Linker Conjugates for ADC, which is composed of a linker and a Ras inhibitor (HY-178838). Z56-L23 can be used for the research of cancer, such as pancreatic cancer.
  • HY-152916
    mp-dLAE-PABC-MMAE
    		98.31%
    mp-dLAE-PABC-MMAE is a agent-linker conjugate for ADC. mp-dLAE-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (HY-15162). mp-dLAE-PABC-MMAE can be used to synthesis antibody-drug conjugates (ADCs).
  • HY-147286A
    Ac-Lys-Val-Cit-PABC-MMAE formic
    		99.96%
    Ac-Lys-Val-Cit-PABC-MMAE (formic) is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitorMonomethyl auristatin E (HY-15162).
  • HY-168317
    LNK2-S
    LNK2-S is a conjugated compound of toxin molecule Exatecan (HY-13631) and Linker, which can be used to synthesize ADC molecule.
  • HY-156897
    Val-Cit-amide-Ph-Maytansine
    		98.01%
    Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs).
  • HY-164296
    SMP-96745
    		99.42%
    SMP-96745 is a dual-drug targeting linker-drug conjugate and can be used for study of cancer.